We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Settles With GSK for $1.25 Billion Plus Royalties Over Viiv Patent Dispute
Gilead Settles With GSK for $1.25 Billion Plus Royalties Over Viiv Patent Dispute
Gilead Sciences will pay GlaxoSmithKline (GSK) $1.25 billion plus royalties to end a four-year-old patent fight between Gilead and human immunodeficiency virus (HIV)-focused ViiV Healthcare, a company launched in 2009 by GSK with drugmakers Pfizer and Shionogi as shareholders.